Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $21.9552W HIGH $53.65
Volume
633.04 K
Value Traded
18.22 M
Short % Float
16.48%
-1.56%Week
+2.16%1 Month
-18.3%3 Month
-8.86%6 Month
+59.93%5 Year
+59.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.47 B
EPS (TTM)
-2.40
P/E Ratio
-
Ent. Value
1.01 B
Total Shares
55.51 M
Float Shares
34.46 M
Insiders
37.97%
Institutions
69.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MAZE Catalyst Timeline
Dated clinical, regulatory and corporate events for Maze Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Maze Therapeutics, Inc.
73Total events
10Upcoming
9Tier-1 (high impact)
2024 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Trial InitiationMZE782Trial
Initiation of Phase 2 proof-of-concept trial of MZE782 in CKD
chronic kidney disease (CKD)source ↗
◆Oral PresentationPresentation
Maze Therapeutics presentation at Goldman Sachs 47th Annual Global Healthcare Conference 2026
◆Oral PresentationPresentation
Maze Therapeutics presentation at 2026 Jefferies Global Healthcare Conference
◆Trial InitiationMZE782Trial
Phase 2 proof-of-concept trial of MZE782 in PKU to initiate
Phenylketonuria (PKU)source ↗
▼Equity OfferingCorporate
Pricing of $150 million registered offering of common stock and pre-funded warrants
▲Milestone PaymentMZE001Corporate
$20 million milestone payment received from Shionogi for MZE001
Pompe diseasesource ↗
◆Trial InitiationMZE782Trial
Initiation of Phase 2 proof-of-concept trial of MZE782 in PKU
phenylketonuria (PKU)source ↗
▲Topline ReadoutMZE829Clinical Data
Positive topline data from Phase 2 HORIZON trial of MZE829 in broad AMKD
APOL1-Mediated Kidney Disease (AMKD)source ↗
▲Topline ReadoutMZE829Clinical Data
Positive topline data from Phase 2 HORIZON trial of MZE829
APOL1-mediated kidney diseasesource ↗
●Oral PresentationMZE829Presentation
Investor conference call and webcast to discuss HORIZON data
APOL1-mediated kidney diseasesource ↗
◆Oral PresentationPresentation
Maze Therapeutics to present at TD Cowen 46th Annual Health Care Conference
▲Milestone PaymentMZE001Corporate
$20 million milestone achieved from Shionogi for first patient dosed in ESPRIT trial
Pompe diseasesource ↗
▲First Patient DosedMZE001Trial
First patient dosed in global Phase 2 ESPRIT trial of MZE001
Pompe diseasesource ↗
◆Oral PresentationPresentation
Maze Therapeutics to present at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Oral PresentationPresentation
Maze Therapeutics presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Topline ReadoutMZE829Clinical Data
Initial topline readout from Phase 2 HORIZON trial
APOL1-mediated kidney diseasesource ↗
◆Interim AnalysisMZE829Trial
Potential proof of concept interim data readout expected
APOL1 kidney diseasesource ↗
◆Poster PresentationMZE782Presentation
Poster presentation: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Proof-of-Mechanism of MZE782, a Specific Inhibitor of SLC6A19 for the Treatment of CKD: Phase 1 Study in Healthy Adults
chronic kidney diseasesource ↗
◆Poster PresentationMZE782Presentation
Poster presentation: Small Molecule Inhibition of SLC6A19 for the Treatment of CKD
chronic kidney diseasesource ↗
▲First Patient DosedMZE782Trial
First-in-human data from Phase 1 trial of MZE782 reported
phenylketonuria (PKU) and chronic kidney disease (CKD)source ↗
◆Enrollment UpdateMZE829Trial
Enrollment ongoing in Phase 2 HORIZON trial of MZE829
APOL1-mediated kidney disease (AMKD)source ↗
◆Poster PresentationMZE829Presentation
Poster presentation: Multicenter, Observational, Cross-Sectional Study to Estimate the Frequencies of APOL1 Genetic Variants in Adult Black and African American Patients with Proteinuric Kidney Disease
APOL1-mediated kidney diseasesource ↗
◆Oral PresentationMZE829Presentation
Oral presentation: Functional Mapping of APOL1 G1 Reveals Key Regions Modulating Cytotoxicity and Inhibitor Sensitivity
APOL1-mediated kidney diseasesource ↗
◆Oral PresentationMZE782Presentation
Oral presentation: Experimentally Validated SLC6A19 Loss of Function Variants Improve Kidney Function and Reduce Progression to Kidney Failure
chronic kidney diseasesource ↗
◆Oral PresentationPresentation
Maze Therapeutics to participate in four upcoming investor conferences
▲Full ResultsMZE782Clinical Data
Positive first-in-human Phase 1 results for MZE782 in healthy volunteers
Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)source ↗
◆Oral PresentationMZE782Presentation
Investor conference call and webcast to discuss Phase 1 data
Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)source ↗
◆Oral PresentationPresentation
Maze Therapeutics to participate in BTIG Virtual Biotech Conference
◆Oral PresentationPresentation
Maze Therapeutics to participate in H.C. Wainwright 4th Annual Kidney Virtual Conference
◆Topline ReadoutMZE782Clinical Data
Initial data including biomarker and proof-of-mechanism results for MZE782 Phase 1 trial in healthy volunteers
Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)source ↗
◆Oral PresentationPresentation
Maze Therapeutics to present at Jefferies 2025 Global Healthcare Conference
◆Oral PresentationPresentation
Maze Therapeutics presents company overview at H.C. Wainwright BioConnect Investor Conference
◆Enrollment UpdateMZE829Trial
Phase 2 HORIZON trial actively enrolling patients
APOL1 Kidney Disease (AKD)source ↗
Past FDA Catalysts and PDUFA Decisions
How MAZE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | MZE829 (oral, small molecule APOL1 inhibitor) | Phase 2 interim results | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$222M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 44%
Micro Cap(rank 289 of 655)
Percentile Rank
Maze Therapeutics, Inc. faces pipeline headwinds (38/100), with $555M risk-adjusted pipeline value, led by MZE829 in Proteinuric Kidney Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MZE829 Small moleculeNCT06830629 | Proteinuric Kidney Disease | Phase 2 | RECRUITING | 74 | Sep 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MAZE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MZE829 | broad AMKD | Phase 2 | 2026-05-13 | Positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad APOL1-mediated kidney disease (AMKD) demonstrated proof-of-concept, supporting its advancement into a pivotal trial, with additional data expected in late 2026 or early 2027.Read More | Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bernstein HaroldOfficer (President, R&D & CMO) | Option | 16,141 16,141 held | $10.42 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MAZE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3.3 % (-5.7 %) | 150.18 M | 5.03 M | 10.2% ( 465.64 K) |
MAZE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MAZE ranks across every disease it competes in
Competitive Position is a premium feature
See how MAZE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMAZE News
MAZEMaze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, will participate in three investor conferences in September 2026. The events include the Wells Fargo Annual Healthcare Conference, Citi Biopharma Summit, and H.C. Wainwright Global Investment Conference. Live webcasts of these presentations will be available on their website. The company is developing precision medicines targeting kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics Announces Appointments to Its Board of Directors
Maze Therapeutics has appointed Paula Johnson, M.D., and Sophie Kornowski, Pharm.D., to its Board of Directors. These appointments aim to enhance the company's clinical and business expertise as it advances its pipeline, including key milestones for drug candidates MZE829 and MZE782 expected in the coming years. The company focuses on developing precision medicines for kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics has reported its financial results for Q2 2026, highlighting progress in several clinical trials. The Phase 2 HORIZON trial for MZE829 is on schedule, with data expected in late 2026 or early 2027. Additionally, the Phase 2 CIPheR trial for MZE782 in PKU has been initiated, and topline data is anticipated in 2027. The company also noted a strong balance sheet.
Read more →MAZEAPRIL 2026 | MAZE THERAPEUTICS
Maze Therapeutics is focusing on expanding the understanding of SLC6A19 substrates. Their research indicates that SLC inhibition could play a crucial role in protecting the kidneys from the accumulation of nephrotoxic metabolites. This advancement could have significant implications for kidney health.
Read more →MAZEMARCH 2026 | MAZE THERAPEUTICS and Certara, Inc.
The article provides a privacy overview regarding the use of cookies on the MAZE Therapeutics website. It explains the necessity of cookies for website functionality and user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to enhance website performance.
Read more →MAZEMaze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Jason Coloma will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs Global Healthcare Conference on June 10, 2026. The company is known for developing precision medicines for kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial of MZE829, supporting its advancement into pivotal trials. The company is also on track to initiate Phase 2 trials for MZE782 targeting PKU and CKD. With a strong cash position of $528 million, Maze aims to continue its clinical execution through 2029.
Read more →MAZEMaze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics announced a $150 million registered offering of its common stock at $23.50 per share. The offering includes pre-funded warrants and is expected to close on April 23, 2026. The funds will primarily be used for the development of MZE829 and MZE782, targeting kidney and metabolic diseases. The offering has attracted both new and existing investors.
Read more →MAZEMAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Maze Therapeutics, Inc. due to losses reported after a significant stock price decline. Following the announcement of topline results from its Phase 2 HORIZON trial for MZE829, which showed a mean reduction in uACR, Maze's stock dropped about 33%. The investigation will determine if Maze's executive officers complied with federal securities laws regarding this disclosure. Investors who have suffered losses are encouraged to reach out for more information on potentially recovering their investments.
Read more →MAZE▼ -35.2%on this newsshared move
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q4 and full year 2025, highlighting positive topline data from the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026. Additionally, Neil Kumar has joined the Board of Directors, enhancing the company's leadership.
Read more →MAZE▼ -35.2%on this newsshared move
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Maze Therapeutics announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a significant mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease. At week 12, MZE829 led to a 35.6% reduction in uACR, with half of the patients achieving greater than 30% reduction. The treatment was well-tolerated, and the company plans to advance MZE829 into a pivotal program.
Read more →MAZEMaze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Maze Therapeutics, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Jason Coloma, Ph.D., will lead the presentation, which will also be available via live webcast. The company focuses on developing precision medicines for kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Maze Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, showcasing its advancements in precision medicines for kidney and metabolic diseases. CEO Jason Coloma will speak on February 11, 2026. The company is known for its innovative approach using human genetics to develop treatments, with key products in Phase 2 development.
Read more →MAZEMaze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jason Coloma, Ph.D., will discuss the company's advancements in small molecule precision medicines for kidney and metabolic diseases. The event will be available via live webcast and archived for 30 days.
Read more →MAZE▲ +6.6%on this news
NOVEMBER 2025 I MAZE THERAPEUTICS
The article discusses the Phase 1 study of MZE782, a specific inhibitor of SLC6A19, aimed at treating chronic kidney disease (CKD). The study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamic proof-of-mechanism in healthy adults. The findings suggest a positive outlook for MZE782 as a potential therapeutic option for CKD.
Read more →MAZEMaze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q3 2025, highlighting positive first-in-human data from its Phase 1 trial of MZE782. The company plans to initiate two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria and chronic kidney disease. Additionally, the ongoing Phase 2 HORIZON trial of MZE829 is expected to provide topline data by the end of Q1 2026.
Read more →MAZEMaze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Maze Therapeutics announced seven presentations at ASN Kidney Week, showcasing advancements in their MZE782 and MZE829 programs. MZE782, a novel SLC6A19 inhibitor, is in Phase 1 trials for PKU and CKD, while MZE829 is in Phase 2 for APOL1-mediated kidney disease. The company emphasizes the importance of genetic insights in developing effective therapies.
Read more →MAZEMaze Therapeutics to Participate in Four Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in four upcoming investor conferences. The company is known for developing small molecule precision medicines targeting kidney and metabolic diseases. Its leading candidates include MZE829 for kidney disease and MZE782 for phenylketonuria and chronic kidney disease. Live webcasts of these events will be available on their website.
Read more →MAZEOCTOBER 2025 I MAZE THERAPEUTICS
The article provides an overview of cookie usage on the MAZE Therapeutics website, emphasizing the importance of essential cookies for functionality and user experience. It mentions the use of Google Analytics for collecting anonymous visitor data to enhance the site. However, it lacks specific news or updates regarding MAZE Therapeutics.
Read more →MAZEMaze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Maze Therapeutics has appointed Hervé Hoppenot as the new Chairman of the Board, succeeding Charles Homcy, M.D. Hoppenot, who has extensive experience in the biopharmaceutical industry, expressed his commitment to advancing the company's clinical programs, particularly MZE782 and MZE829. The company is well-positioned for growth with recent funding and promising clinical data.
Read more →MAZE▲ +54.8%on this news
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
Maze Therapeutics has announced a successful oversubscribed private placement, raising approximately $150 million. The funds will be used to further develop its lead candidates, MZE829 and MZE782, targeting kidney and metabolic diseases. The placement involves participation from both new and existing investors and is set to close on September 12, 2025.
Read more →MAZE▲ +54.8%on this newsshared move
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Maze Therapeutics announced positive Phase 1 trial results for MZE782, an oral SLC6A19 inhibitor. The trial demonstrated significant increases in urinary phenylalanine excretion and a favorable safety profile, supporting its advancement to Phase 2 trials for treating phenylketonuria (PKU) and chronic kidney disease (CKD) expected to start in 2026.
Read more →MAZE▲ +5.7%on this news
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
Maze Therapeutics has appointed Misbah Tahir as Chief Financial Officer, effective immediately. His extensive experience in the biopharmaceutical sector is expected to support Maze's growth strategy, particularly as the company approaches significant clinical milestones. The company is focused on developing precision medicines for kidney and metabolic diseases, with promising data expected soon.
Read more →MAZEMaze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CK
Maze Therapeutics has reported its second-quarter financial results for 2025, showcasing progress in its clinical trials. The company is expecting to release important proof of mechanism data for its MZE782 compound by Q3 2025, which targets conditions such as phenylketonuria and chronic kidney disease. Additionally, the Phase 2 HORIZON trial of MZE829 is actively enrolling patients, with initial results anticipated by early 2026. Despite its strong cash position, Maze reported no license revenue this quarter and incurred a net loss of $33.7 million.
Read more →MAZE▲ +6%on this news· ran to +19% by day 3
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
Maze Therapeutics will present an overview at the Jefferies 2025 Global Healthcare Conference on June 5, 2025. CEO Jason Coloma, Ph.D., will lead the presentation, which will be available via a live webcast. The company focuses on developing precision medicines for renal, metabolic, and cardiovascular diseases.
Read more →MAZE▼ -8.1%on this news
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1
Maze Therapeutics reported its financial results for the first quarter of 2025, indicating a solid cash position of $294.4 million to fund ongoing clinical trials. The company emphasized progress in its MZE829 Phase 2 trial for APOL1 Kidney Disease, with initial data expected in Q1 2026, while MZE782 is currently in Phase 1 trials with results anticipated in Q3 2025. The net loss for this quarter was $32.8 million, reflecting an increase in R&D spending as therapies advance. Despite the losses, the company expresses optimism about its pipeline and the potential market impact.
Read more →MAZEMaze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Maze Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025. CEO Jason Coloma, Ph.D., will present an overview of the company and engage in one-on-one meetings. The presentation will be accessible on the company's website, with an archived replay available for 60 days. This participation reflects Maze's commitment to transparency and investor relations as they advance their precision medicine initiatives.
Read more →MAZEMaze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782
Maze Therapeutics reported its fourth quarter and full-year financial results for 2024, revealing a net income of $52.2 million thanks to license revenue from a partnership with Shionogi. The company is advancing its MZE829 and MZE782 candidates through multiple clinical trials, with significant milestones expected in the coming years, including initial data from the MZE829 Phase 2 trial in early 2026. The company also strengthened its financial position through a $140 million IPO, providing a cash runway into the second half of 2027. Continued financial losses highlight challenges ahead as Maze pushes forward with its developmental pipeline.
Read more →MAZEMaze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics has begun dosing patients in its Phase 2 HORIZON clinical trial for MZE829, an oral APOL1 inhibitor aimed at treating APOL1 kidney disease (AKD). The trial includes a diverse group of patients, reflecting various severity levels of the disease, with a primary endpoint focusing on reducing proteinuria. The company's approach seeks to establish proof of concept for MZE829, which may serve as a significant advancement in managing AKD, affecting over one million patients in the U.S. There is anticipation for interim data readout by early 2026.
Read more →MAZEMaze Therapeutics Announces Pricing of Upsized Initial Public Offering
Maze Therapeutics has announced the pricing of its upsized initial public offering, offering 8,750,000 shares at $16.00 each, projected to yield gross proceeds of $140 million. The company plans to begin trading on the Nasdaq under the ticker 'MAZE' on January 31, 2025. The offering includes a 30-day option for underwriters to purchase additional shares. The close of the offering is expected on February 3, 2025, pending customary closing conditions. Maze focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases.
Read more →MAZEJANUARY 2025 I MAZE THERAPEUTICS
The article discusses the privacy overview and cookie usage on the MAZE Therapeutics website. It highlights the importance of essential cookies for website functionality and user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data. No specific news or updates about MAZE Therapeutics are provided.
Read more →MAZEAfter deal about-face and a spinout, Maze assembles $115M Series D
Maze Therapeutics has successfully raised $115 million in a Series D funding round following a strategic deal reversal and a spinout. This funding aims to support the company's ongoing research and development efforts. The financial backing reflects investor confidence in Maze's potential despite recent organizational changes.
Read more →MAZEMaze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline
Maze Therapeutics has completed a $115 million Series D financing, co-led by Frazier Life Sciences and Deep Track Capital. This funding will support the advancement of its lead programs, MZE829 and MZE782, targeting chronic renal diseases. The company aims to optimize its Phase 2 trial for MZE829 and expects data from its Phase 1 trial of MZE782 in late 2025.
Read more →MAZENOVEMBER 2024 I MAZE THERAPEUTICS
The article discusses the privacy overview and cookie usage on the Maze Therapeutics website. It highlights the necessity of cookies for website functionality and user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website.
Read more →MAZEOCTOBER 2024 I MAZE THERAPEUTICS
The article discusses the use of cookies on the Maze Therapeutics website, emphasizing their role in enhancing user experience and website functionality. It mentions the use of Google Analytics for collecting anonymous visitor data. However, there are no specific news events or updates related to Maze Therapeutics.
Read more →MAZEMaze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics announced positive results from the Phase 1 trial of MZE829, an oral inhibitor targeting APOL1 for treating APOL1-mediated kidney disease. The trial showed that MZE829 was well tolerated and supported once daily dosing. The company plans to advance to a Phase 2 trial in early 2025, aiming to include a diverse patient population.
Read more →MAZEMaze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Society of Nephrology’s Kidney Week and American Society of Human Genetics Annual Meeting
Maze Therapeutics announced the presentation of new data for its clinical programs MZE829 and MZE782 at upcoming conferences. The Phase 1 trial data for MZE829 supports its advancement to Phase 2, expected to start in early 2025. Additionally, preclinical data for MZE782 supports its recent initiation of Phase 1 trials in healthy volunteers.
Read more →MAZEMaze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease
Maze Therapeutics has initiated a Phase 1 clinical trial for MZE782, a potential first-in-class treatment for chronic kidney disease (CKD). The trial, involving healthy volunteers, aims to evaluate the safety and efficacy of MZE782, which targets the SLC6A19 transporter. Initial results are expected in the second half of 2025, potentially benefiting millions of CKD patients with inadequate responses to current therapies.
Read more →MAZESEPTEMBER 2024 I MAZE THERAPEUTICS
The article provides an overview of the privacy policy and cookie usage on the Maze Therapeutics website. It outlines the types of cookies used, including essential and third-party cookies, and explains their functions in enhancing user experience. The article also mentions the use of Google Analytics for collecting anonymous visitor data.
Read more →MAZEMaze Corporate Presentation – July 2024
The article provides an overview of cookie usage on the Maze website, detailing the types of cookies used, including essential and third-party cookies. It emphasizes the importance of cookies for website functionality and user experience. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data.
Read more →MAZEAfter FTC stalled Sanofi deal, Shionogi secures Maze’s Pompe disease drug for $150M
Shionogi has acquired Maze's Pompe disease drug for $150 million following a stalled deal with Sanofi due to FTC intervention. This acquisition is seen as a strategic move to bolster Shionogi's offerings in the biopharma sector. The deal highlights the ongoing interest in treatments for Pompe disease.
Read more →MAZEShionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. has entered into an exclusive worldwide license agreement with Maze Therapeutics for MZE001, a novel oral therapy aimed at treating Pompe disease. This agreement, which includes a $150 million upfront payment and potential milestone payments, positions Shionogi to expand its pipeline in rare diseases. MZE001 is expected to address unmet medical needs by reducing glycogen accumulation in patients.
Read more →MAZEMaze Therapeutics to Participate in Upcoming Investor Conferences
Maze Therapeutics announced its participation in several upcoming investor conferences in February and March 2024. The events include presentations and one-on-one meetings at the Evercore ISI 2024 Emerging Biotech Conference, Cowen Healthcare Conference, and Leerink Partners Global Biopharma Conference. This engagement highlights the company's commitment to transparency and investor relations.
Read more →MAZE2024 J.P. Morgan Healthcare Conference Presentation
The article provides an overview of cookie usage on a website, detailing essential and third-party cookies. It emphasizes the importance of cookies for user experience and website functionality. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data.
Read more →MAZEMaze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics has commenced dosing in a Phase 1 trial for MZE829, an oral APOL1 inhibitor aimed at treating APOL1-mediated kidney disease. This trial represents the second program from their Compass platform to enter clinical development. The trial will assess safety and pharmacokinetics in healthy volunteers, with results expected in late 2024.
Read more →MAZEMaze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Maze Therapeutics announced that the FTC is seeking to block its collaboration with Sanofi regarding the license agreement for MZE001, a treatment for Pompe disease. This complaint marks a significant regulatory challenge, as it is reportedly the first time the FTC has attempted to block a license for a Phase 1 investigational medicine. Maze's CEO expressed disappointment and plans to review the complaint while continuing to advance other programs.
Read more →MAZENOVEMBER 2023 | MAZE THERAPEUTICS
The article provides an overview of the cookie policy for the Maze Therapeutics website. It details the use of essential cookies for website functionality and analytics. The content emphasizes user experience and the importance of cookies in recognizing returning visitors and measuring website performance.
Read more →MAZEMaze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease
Maze Therapeutics presented promising preclinical data on its APOL1 inhibitor, MZE829, at the ASN Kidney Week 2023. The data indicate a significant reversal of albuminuria in a chronic mouse model of APOL1-mediated kidney disease. The company plans to initiate a Phase 1 trial by the end of 2023, marking a significant step toward clinical evaluation.
Read more →MAZEMaze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria
Maze Therapeutics will present new findings on APOL1 kidney disease at Kidney Week 2023. The research showcases the reversal of albuminuria in a chronic mouse model through small molecule inhibition of APOL1. This presentation reflects the company's commitment to developing innovative treatments for genetic diseases.
Read more →MAZEOCTOBER 2023 | MAZE THERAPEUTICS Million Veteran Program and Vanderbilt University Medical Center
The article provides a privacy overview regarding the use of cookies on the MAZE Therapeutics website. It highlights the necessity of essential cookies for website functionality and measurement purposes. Additionally, it mentions the use of Google Analytics for collecting anonymous visitor data to improve the website experience.
Read more →MAZEMaze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease
Maze Therapeutics has published research in JASN demonstrating that the APOL1 variant p.N264K is associated with a reduced risk of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) among carriers of high-risk variants. This discovery enhances the understanding of APOL1's role in kidney injury and supports the development of a small molecule inhibitor aimed at treating APOL1-mediated kidney disease, with a Phase 1 trial expected to start by the end of 2023.
Read more →MAZEMaze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Maze Therapeutics will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference on September 26, 2023. The management will engage in a fireside chat, which will be available via a live webcast. The company focuses on leveraging genetic insights to develop precision medicines for common diseases.
Read more →About Maze Therapeutics, Inc.
Headquarters171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next MAZE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime